Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients: A cross-sectional study

Kata Judit Szántó, Zoltán András Mezei,Diána Kata,Imre Földesi,Tibor Nyári,Anna Fábián,Mariann Rutka,Renáta Bor,Anita Bálint,Ágnes Milassin,Zoltán Szepes,Ferenc Nagy,Károly Palatka,Klaudia Farkas,Tamás Molnár

Central European Journal of Gastroenterology and Hepatology（2021）

Cited 0|Views18

No score

Abstract

In this cross-sectional, real-life study we have investigated the potential association between 6-thioguanine nucleotide (6-TGN) and anti-TNF [infliximab (IFX), adalimumab (ADA)], anti-drug antibody levels and body composition parameters. Based on our results thiopurine and anti-TNF combination therapy resulted in decreased antibody formation in IFX-treated patients. AZA-ADA-treated patients showed increased anti-TNF drug concentrations, regardless of antibody formation. Drug metabolites did not correlate with body composition parameters.

Translated text

Key words

inflammatory bowel disease patients,inflammatory bowel disease,thiopurines,drug metabolite levels,anti-tnfs,cross-sectional

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined